{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:55:20Z","timestamp":1788479720292,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,5,10]],"date-time":"2007-05-10T00:00:00Z","timestamp":1178755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Remission rates of 76, 69\u00b75 and 64\u00b73% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2\u20135\u00a0years after cabergoline (CAB) withdrawal.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To report the estimated recurrence rate at 24\u201396\u00a0months after CAB withdrawal and indicate predictors of disease remission.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Observational, analytical, prospective.<\/jats:p><jats:p><jats:bold>Patients\u2002<\/jats:bold> Of 381 previously untreated de novo patients with hyperprolactinaemia, 221 (58%) (173 women, 48 men; 27 with NTH, 115 with micro\u2010, and 79 with macroprolactinoma) were studied.<\/jats:p><jats:p><jats:bold>Measurements\u2002<\/jats:bold> Using multiple regression analysis the diagnostic accuracy of nadir PRL levels (<jats:italic>t<\/jats:italic>\u00a0=\u00a07\u00b76, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b70001) and nadir maximal tumour diameter at CAB withdrawal (<jats:italic>t<\/jats:italic>\u00a0=\u00a03\u00b79, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b7001) was analysed using receiver operating characteristic (ROC) curves.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The recurrence of hyperprolactinaemia was 25\u00b79, 33\u00b79 and 53\u00b71% in patients with NTH, micro\u2010 or macroprolactinoma, respectively. To predict the last PRL level after withdrawal, the optimum cut\u2010off of nadir PRL levels at withdrawal was 162\u00a0mU\/l (5\u00b74\u00a0\u00b5g\/l) [sensitivity (95% CI) 76% (67\u201384%), specificity 65% (51\u201377%)] and that of nadir maximal tumour diameter was 3\u00b71\u00a0mm [sensitivity 52% (41\u201363%), specificity 86% (79\u201391%)]. The patients achieving both nadir PRL levels\u00a0\u2264\u00a0162\u00a0mU\/l and maximal tumour diameter\u00a0\u2264\u00a03\u00b71\u00a0mm (<jats:italic>n<\/jats:italic>\u00a0=\u00a0111) at CAB withdrawal had a significantly lower Kaplan\u2013Meier estimate of recurrence of hyperprolactinaemia (20%) at 24\u201396\u00a0months than those who did not fulfil any of these criteria [(<jats:italic>n<\/jats:italic>\u00a0=\u00a038) 90%; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b70001]. Patients achieving nadir PRL levels \u2264\u00a0162\u00a0mU\/l (<jats:italic>n<\/jats:italic>\u00a0=\u00a026) or maximal tumour diameter \u2264\u00a03\u00b71\u00a0mm during CAB treatment (<jats:italic>n<\/jats:italic>\u00a0=\u00a046) had an estimated recurrence rate of hyperprolactinaemia of 50 and 56%, respectively.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Persistent remission of hyperprolactinaemia without any evidence of tumour re\u2010growth after 24\u201396\u00a0months of CAB withdrawal occurred in the majority of patients with NTH and microprolactinoma and in about half of those with macroprolactinoma. Nadir PRL levels and maximal tumour diameter at CAB withdrawal of \u2264\u00a0162\u00a0mU\/l and \u2264\u00a03\u00b71\u00a0mm predicted remission of hyperprolactinaemia in 80% of patients.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2007.02905.x","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T13:35:56Z","timestamp":1182000956000},"page":"426-433","source":"Crossref","is-referenced-by-count":95,"title":["Predictors of remission of hyperprolactinaemia after long\u2010term withdrawal of cabergoline therapy"],"prefix":"10.1111","volume":"67","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Di Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermelinda","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cappabianca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Caranci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Elefante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi M.","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sossio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,7,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-9998"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410063311403"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.6.2338"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1340454"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.1300952.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.11.3574"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.3.876"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348016"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinaemia: a study in 455 patients","volume":"84","author":"Verhelst J.","year":"1999","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03343573"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009913200542"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.6.2247"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.11.5256"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030979"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030852"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-62-6-1296"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00809.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","article-title":"Surgical treatment of prolactin\u2010secreting pituitary adenomas: early results and long\u2010term outcome","volume":"87","author":"Losa M.","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022657"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90418-7"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90480-X"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb03175.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","article-title":"Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin\u2010secreting pituitary tumors","volume":"41","author":"Maxons W.S.","year":"1984","journal-title":"Fertility and Sterility"},{"key":"e_1_2_6_25_2","first-page":"139","article-title":"Follow\u2010up of patients with prolactinoma after discontinuation of long\u2010term therapy with bromocriptine","volume":"104","author":"Zarate A.","year":"1983","journal-title":"Acta Endocrinologica (Copenhagen)"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-60-4-764"},{"key":"e_1_2_6_27_2","first-page":"817","volume-title":"Prolactin. Basic and Clinical Correlates","author":"Winkelmann W.","year":"1985"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb01163.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.8.3578"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02293.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00289.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01016.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-68-2-412"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","article-title":"The natural history of untreated microprolactinomas","volume":"48","author":"Sisam D.A.","year":"1987","journal-title":"Fertility and Sterility"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(92)90094-F"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01190.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.7.2102"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.9.3053"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01770.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-5084-3"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02461.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1480325"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2007.02905.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2007.02905.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:43:39Z","timestamp":1697197419000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2007.02905.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,20]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2265.2007.02905.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02905.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,20]]}}}